BCLC Stage Decoder — What 0 / A / B / C / D Actually Mean
When your doctor says "You are Stage B" — what does that mean? This page translates each of the five BCLC stages into plain language: the reality, the goal, and the options. No jargon. No fear.
Quick Answer — If You Have 30 Seconds
BCLC has five stages. Each has a different goal:
- Stage 0 — Very early. Small tumor, healthy liver. Goal: cure. Options: ablation, resection.
- Stage A — Early. Small tumor(s), preserved liver. Goal: cure. Options: resection, ablation, transplant.
- Stage B — Intermediate. Multiple tumors, no spread. Goal: control. Options: TACE, TARE, immunotherapy (in B2/B3).
- Stage C — Advanced. Vascular invasion or spread. Goal: extend survival. Options: combination immunotherapy (Atezolizumab + Bevacizumab, etc.).
- Stage D — End-stage. Liver failing or poor physical status. Goal: comfort. Options: best supportive care.
Key point: Stage B is no longer one block — it is subclassified into B1, B2, B3 (see section below). And Stage C is not "palliative only" — since 2025, it means immunotherapy.
The Common Misconception — and What Actually Matters
Myth: "Stage B means limited options. Stage C means the end."
Reality: In 2025, Stage B can mean TACE or immunotherapy — and some Stage B patients reach Stage A through downstaging, becoming transplant candidates. Stage C means combination immunotherapy — not "the end."
The key point: Your stage is a starting point, not a verdict. If your doctor only looks at the stage and never at you, ask for a second opinion.
Who This Page Is For — and Who It Is Not For
Radical honesty is the first step of any good decision.
This page is for you if…
- Your doctor said "You are Stage B" (or A, C, D) — and you want to know what that actually means
- You have been told "nothing more can be done" — and you want to understand your stage before seeking a second opinion
- You are between stages (borderline B/C) and want to know what questions to ask
- You want to compare your options across stages — not just inside one
- You are a caregiver trying to understand a family member's stage
This page is not for you if…
- You are looking for what changed in the 2025 guideline — see the BCLC 2025 companion page
- You have cholangiocarcinoma or another primary liver cancer — BCLC is HCC-specific
- You want an individual survival prediction — BCLC provides stage-level survival, not individual
- You want us to recommend a specific hospital — we are not a booking agency
What Patients Actually Ask About Their Stage
"I am 56. In Tehran they said: 'Stage C — palliative only.' I was not looking for a 'stage' — I was looking for an option. At a specialized center, the doctor said: 'Stage C in 2025 means immunotherapy — not the end.' I am not saying Stage C performed a miracle — I am saying Stage C was explained correctly."— Illustrative, de-identified example (fictional; not a real patient, not a clinical outcome claim)
- What is my stage — and what does it mean in plain language?
- What is the difference between B1, B2, and B3?
- If I am Stage B, can I still become a transplant candidate?
- What does Stage C in 2025 actually mean — is there still hope?
- If I am Stage D, is there any other option?
- Why does my doctor compare BCLC to TNM — which one matters more?
- If my stage is "borderline" between B and C, what should I do?
The Five Stages — Decoded
Each card below gives you the same four things: the reality, the goal, the options, and one takeaway.
Very Early
One tumor, ≤ 2 cm, excellent liver function, ECOG 0.
Cure.
Ablation · resection.
Early
One tumor, or up to 3 nodules ≤ 3 cm; preserved liver function; ECOG 0.
Cure.
Resection · ablation · liver transplant (Milan criteria).
Intermediate
Multiple tumors, preserved liver function, ECOG 0 — no vascular invasion or extrahepatic spread.
Control tumor growth · preserve liver function.
TACE · TARE · immunotherapy (B2/B3) · downstaging to transplant.
Advanced
Vascular invasion and/or extrahepatic spread; preserved liver function; ECOG 0–2.
Extend survival · maintain quality of life.
Combination immunotherapy (e.g., Atezolizumab + Bevacizumab, Durvalumab + Tremelimumab) · clinical trials.
End-stage
End-stage liver function or ECOG ≥ 3 (bed-bound > 50% of the day) — regardless of tumor burden.
Comfort · quality of life.
Best supportive care · symptom management · palliative care.
Stage B Is Not One Stage — It Is Three
In 2025, Stage B is subclassified into B1, B2, and B3. This matters more than many patients realize — it can change your entire treatment path.
Low tumor burden. Small, well-defined nodules without portal vein invasion. Liver function preserved. Usually within up-to-7 criteria.
TACE remains the standard. Some patients may even be re-evaluated for transplant after downstaging.
Intermediate tumor burden. Larger or more numerous nodules, possibly with limited portal vein branch involvement. Within preserved liver function.
TACE may still be used — but combination approaches (TACE + systemic therapy) or upfront immunotherapy may be considered in a tumor board.
High tumor burden. Extensive intrahepatic disease, "TACE-untreatable" by current criteria. Liver function preserved but tumor burden overwhelming.
Systemic therapy (immunotherapy combinations) is often preferred over TACE. Some patients may be candidates for HAIC or clinical trials.
The question to ask
If you are Stage B, ask your doctor: "Am I B1, B2, or B3?" If they cannot answer — or if they treat all Stage B the same way — that is a signal to seek a multidisciplinary review or a second opinion. The B1/B2/B3 distinction is what separates a modern 2025 review from a 2018 one.
What Goes Into Your Stage — Four Factors, Not One
BCLC is not just "how big the tumor is." Four factors are combined. Understanding them helps you ask better questions.
Tumor burden
Number of nodules, maximum size, vascular invasion (portal vein), extrahepatic spread.
Separates Stage 0/A from B/CLiver function
Child-Pugh score, ALBI grade, portal hypertension. Measured by blood tests (bilirubin, albumin, INR) and imaging.
Determines treatment eligibility and Stage DPerformance status
ECOG scale 0–4. ECOG ≥ 3 (bed-bound > 50% of the day) defines Stage D regardless of tumor size.
Overrides tumor-based stagingTumor biology
Molecular profile, ctDNA, response to prior therapy. A growing factor — especially for access to CAR-T or trial eligibility.
Emerging — refines prognosis within stagesWhen BCLC Staging Is Not the Whole Picture
BCLC is the global standard — but it is a framework, not a verdict.
Do not rely on BCLC alone if…
- Your cancer is a rare subtype — BCLC is designed for HCC, not cholangiocarcinoma or metastases
- Your case is borderline B/C — rigid staging fails; a multidisciplinary tumor board (MDT) review is essential
- You are seeking clinical trial access — trial eligibility has its own criteria beyond BCLC
- You have been told "nothing more can be done" — a second opinion may identify downstaging or trial options not available locally
- You are considering treatment abroad — different centers may apply BCLC differently
A second opinion is most valuable when…
- Your stage is borderline (e.g., between B and C)
- Your first-line treatment has failed and you need a new plan
- You are considering transplant — different centers have different downstaging criteria
- You want to know whether clinical trials are an option
- You want to know whether a different country has a relevant specialist center
Which stage tends to benefit most from a second opinion?
In practice, borderline B/C patients and Stage B patients who may be downstageable benefit most — because those are the cases where different centers disagree. Stage 0/A patients with clear curative options rarely benefit from abroad review. Stage D patients benefit from palliative-care-focused second opinions, not new-treatment ones. See which stage pathway fits your case →
Frequently Asked Questions About BCLC Staging
What does my BCLC stage actually mean?
BCLC combines three things: tumor burden, liver function, and performance status. The result places you in one of five stages — 0, A, B, C, or D — each with a different goal (cure → control → extend survival → comfort). Your stage is a starting point for discussion, not a verdict. The five stages are decoded in detail above.
What is the difference between B1, B2, and B3?
Stage B is no longer one block — it is subclassified into B1 (low tumor burden), B2 (intermediate burden), and B3 (high burden / TACE-untreatable). B1 is typically a TACE candidate. B3 is more likely to receive systemic therapy (immunotherapy). B2 is the borderline zone where tumor board review matters most. If your doctor treats all Stage B the same way, ask: "Am I B1, B2, or B3?"
Can I go down in stage after treatment?
Yes — this is called downstaging (or treatment stage migration). Successful TACE, systemic therapy, or radiation can shrink the tumor enough that a patient initially Stage B or C becomes eligible for curative options like resection or transplant. The criteria vary by center, but BCLC 2025 formally recognizes the concept. For what changed in the 2025 update specifically, see the BCLC 2025 companion page.
Is BCLC the same as TNM staging?
No. TNM classifies only the anatomical tumor extent. BCLC additionally integrates liver function (Child-Pugh) and performance status (ECOG). For HCC, where liver reserve often matters as much as tumor size, BCLC is more practical for treatment allocation. Some centers report both — the two are not interchangeable.
What is the life expectancy for BCLC Stage B?
Life expectancy varies significantly based on the B1/B2/B3 subclassification, liver function, treatment response, and access to care. With the 2025 subclassification and combination therapies, outcomes within Stage B have improved. Because these are population-level ranges — not individual predictions — your oncology team should give you case-specific guidance. Ask them directly: "Given my stage, my liver function, and my response so far, what is a realistic range for me?"
When should I get a second opinion on my BCLC staging?
A second opinion is most valuable when: your stage is uncertain or borderline; you are between B and C; first-line therapy has failed; you are considering transplant (downstaging criteria vary by center); or you want to know whether clinical trials are an option. Expert multidisciplinary review can identify treatment pathways not available at your local center. It is not a sign of distrust — it is a sign of diligence.
What role does imaging play in BCLC staging?
Multiphasic contrast-enhanced CT or MRI is essential. Imaging determines tumor number, size, vascular invasion, and extrahepatic spread — the tumor-burden variables that drive the stage. Imaging quality matters: without proper multiphasic imaging, staging can be inaccurate, and the treatment plan may be based on incomplete information.
If Your Stage Left You With More Questions
This page is educational. If you want to understand which treatment pathway matches your stage, the Pathway Finder is an informational self-assessment — no clinical decision is made on your behalf.
Continue Your Research
BCLC 2025 Companion
What changed in 2025 — CUSE framework, stage migration, first-line drugs.
Liver Cancer Overview
Diagnosis, staging, treatment options — in plain language.
Treatment Options
TACE, TARE, immunotherapy, transplant — explained.
Palliative Care
Comfort-focused care — for Stage D and beyond.
Pathway Finder
Guided treatment-path assessment — no data stored.
References
- Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update. J Hepatol. 2025. doi:10.1016/j.jhep.2025.10.015
- European Association for the Study of the Liver (EASL). Clinical Practice Guidelines on the management of hepatocellular carcinoma. easl.eu/clinical-practice-guidelines
- NCCN Clinical Practice Guidelines in Oncology — Hepatobiliary Cancers. nccn.org
- Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835-853. (Original BCLC framework.)
- CancerCareE — Financial Transparency and Editorial Policy. cancercaree.com/financial-transparency/